New Delhi: Novavax Covid-19 vaccine showed a strong efficacy against coronavirus and its variants, in a large US study, the company said in a release on Monday. Novavax Covid-19 vaccine is over 90 per cent effective in preventing symptomatic Covid and 100 per cent effective at preventing moderate and severe symptoms, the American pharmaceutical company said. The Covid-19 shot was 93 per cent effective against variants of Covid-19, it added.
The NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine, demonstrated 100 per cent protection against moderate and severe disease, 90.4 per cent efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial, the official statement read. “93% efficacy against predominantly circulating Variants of Concern and Variants of Interest,” it added.
NEW DATA RELEASE: Novavax #COVID19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial https://t.co/lIOiQXxDtD pic.twitter.com/4ePHxDpziZ
— Novavax (@Novavax) June 14, 2021
The US biotech firm had conducted a study of 29,960 participants across 119 sites in the US and Mexico to evaluate the efficacy, safety, and immunogenicity. The study emphasized recruiting a representative population of communities and demographic groups most impacted by the disease, it added.
The study was conducted from January 25 through April 30, 2021 — a time when the Alpha (B.1.1.7) variant, first identified in the UK, became the predominant strain in the US. Other strains, including Variants of Interest (VoI) and Variants of Concern (VoC), were also on the rise during that period.
“These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent Covid-19 amid ongoing genetic evolution of the virus. Our vaccine will be a critical part of the solution to Covid-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the U.S. Government,” said Gregory M Glenn, MD, President of Research and Development, Novavax.
Novavax also announced that it is waiting for regulatory approvals which could happen in the third quarter of this year. It plans to manufacture 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021.
Many tropical countries including India, have been waiting for Covid-19 vaccines that do not require cryogenic storage setups.
Unlike other Covid-19 vaccines, Novavax’s vaccine does not need ultra-low temperatures for storage. The biotech company added that its Covid-19 vaccine can be “stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution.”